AGEINGRosiglitazone improves contextual fear conditioning in aged ratsGemma, Carmelina1 2; Stellwagen, Heather2; Fister, Matthew2; Coultrap, Steven J.3; Mesches, Michael H.3 4; Browning, Michael D.3; Bickford, Paula C.1 2 CAAuthor Information 1James A. Haley VA Hospital, 13000 Bruce B. Downs Blvd., Tampa, FL, 33612 2Center of Excellence for Aging and Brain Repair, Dept. of Neurosurgery, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL 33612 3University of Colorado Health Science Center, 4200 East 9th Ave, Denver, CO 80262 4Denver VA Medical Center, 1100 Clermont St., Denver, CO 80220, USA CA,2Corresponding Author and Address: email@example.com Received 18 June 2004; accepted 2 August 2004 NeuroReport: October 5th, 2004 - Volume 15 - Issue 14 - p 2255-2259 Buy SDC Abstract Experimental, clinical, and epidemiologic studies indicate that non-steroidal anti-inflammatory drugs (NSAIDs) are beneficial in Alzheimer's disease and other neuroinflammatory processes. One possible mechanism is an interaction with peroxisome proliferator-activated receptors (PPARs). We examined the effect of a specific PPARγ agonist, rosiglitazone, on contextual fear conditioning in aged rats. Male rats (20-months-old) were administered rosiglitazone in the diet for 2 months prior to behavioral testing. Young control and aged rats fed rosiglitazone froze significantly more than did the aged control rats in a hippocampal-dependent fear conditioning task. Rosiglitazone had no effect hippocampal interleukin-1β levels, markers of oxidative damage, and NMDA receptor expression. Therefore, activation of PPARγ prevented age-related deficits in hippocampal function. © 2004 Lippincott Williams & Wilkins, Inc.